Patents by Inventor Antonios Matzouranis

Antonios Matzouranis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230248736
    Abstract: Provided herein are methods for the treatment of avoiding loss of taste response while treating a chronic cough patient with a selective P2X3 modulator.
    Type: Application
    Filed: September 14, 2022
    Publication date: August 10, 2023
    Inventors: Denis GARCEAU, Antonios MATZOURANIS, Roberto BELLINI, Kemal PAYZA, Nathalie CHAURET, Susan E. BROWNE
  • Publication number: 20220160724
    Abstract: Provided herein are methods for the treatment of avoiding loss of taste response while treating a chronic cough patient with a selective P2X3 modulator.
    Type: Application
    Filed: February 11, 2022
    Publication date: May 26, 2022
    Inventors: Denis GARCEAU, Antonios MATZOURANIS, Roberto BELLINI, Kemal PAYZA, Nathalie CHAURET, Susan E. BROWNE
  • Publication number: 20210386751
    Abstract: Provided herein are methods for treating endometriosis, endometriosis-associated pain, and endometriosis-associated symptoms in a mammal in need thereof with a P2X3 modulator.
    Type: Application
    Filed: August 30, 2021
    Publication date: December 16, 2021
    Inventors: Antonios MATZOURANIS, Denis GARCEAU, Roberto BELLINI
  • Publication number: 20210346391
    Abstract: Methods of treating pruritus in a mammal with a P2X3 antagonist are disclosed. Said P2X3 antagonist is preferably a compound of Formula (I). Said pruritus may be associated with an inflammatory skin disorder, an infectious skin disease, an autoimmune skin disease or a pregnancy-related skin disease. The P2X3 antagonist may be administered by intravenous administration, subcutaneous administration, oral administration, inhalation, nasal administration, topical administration or ophthalmic administration and may be used in conjunction with a NK-1 antagonist. The P2X3 antagonist acts by inhibiting pathological ATP release associated with hyperexcitability of afferent pruriceptive neurons, thus dampening peripheral hypersensitivity to itch via broad mechanism independent on the pathological stimuli acting at itch receptors.
    Type: Application
    Filed: October 9, 2019
    Publication date: November 11, 2021
    Inventors: Antonios MATZOURANIS, Nathalie CHAURET, Denis GARCEAU
  • Publication number: 20210322432
    Abstract: Provided herein are methods for the treatment of avoiding loss of taste response while treating a chronic cough patient with a selective P2X3 modulator.
    Type: Application
    Filed: June 29, 2021
    Publication date: October 21, 2021
    Inventors: Denis GARCEAU, Antonios MATZOURANIS, Roberto BELLINI, Kemal PAYZA, Nathalie CHAURET, Susan E. BROWNE
  • Publication number: 20210069201
    Abstract: Provided herein are methods for the treatment of avoiding loss of taste response while treating a chronic cough patient with a selective P2X3 modulator.
    Type: Application
    Filed: November 17, 2020
    Publication date: March 11, 2021
    Inventors: Denis GARCEAU, Antonios MATZOURANIS, Roberto BELLINI, Kemal PAYZA, Nathalie CHAURET, Susan E. BROWNE
  • Publication number: 20200230148
    Abstract: The current application relates to the use of a selective P2X3 antagonist for avoiding loss of taste response while treating a chronic cough in warm-blooded animals; wherein said selective P2X3 antagonist is selective for P2X3 homomeric receptor antagonism versus P2X2/3 heteromeric receptor antagonism.
    Type: Application
    Filed: September 14, 2018
    Publication date: July 23, 2020
    Inventors: Denis GARCEAU, Antonios MATZOURANIS, Roberto BELLINI, Kemal PAYZA, Nathalie CHAURET, Susan E. BROWNE
  • Patent number: 10111883
    Abstract: Provided herein are methods for the treatment of avoiding loss of taste response while treating a chronic cough patient with a selective P2X3 modulator.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: October 30, 2018
    Assignees: BELLUS HEALTH COUGH INC., NEOMED INSTITUTE
    Inventors: Denis Garceau, Antonios Matzouranis, Roberto Bellini, Kemal Payza, Nathalie Chauret, Susan E. Browne